Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Study to Evaluate the Safety and Tolerability Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis

Next Previous
Trial Profile

Phase 1/2a Study to Evaluate the Safety and Tolerability Intra-articular CX-011 to Treat Moderate to Severe Pain From Knee Osteoarthritis

Status: Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CX-011 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions
  • Sponsors CarthroniX

Most Recent Events

  • 13 Apr 2022 New trial record
  • 11 Apr 2022 According to a CarthroniX media release, the company expects to file an Investigational New Drug (IND) application with the US Food and Drug Administration seeking approval of a Phase 1/2a randomized controlled study of CX-011 later this year and advance this study into early 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top